Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments

doi:10.4254/wjh.v8.i17.703

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15571)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-9) series, Tables (1-8) series.

Item

Count

PDF

1647

WORD

379

HTML

7718

Figures (1-9)

449

Tables (1-8)

319

Sum=10512

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

479

Download

1093

Sum=1572

Publishing Process of This Article

Item

Count

Browse

1301

Download

2186

Sum=3487

Jun 18, 2016 (publication date) through Apr 18, 2025

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Hepatol. Jun 18, 2016; 8(17): 703-715
Published online Jun 18, 2016. doi: 10.4254/wjh.v8.i17.703

Table 3 Definitions of the c-Japan Integrated Staging score and the biomarker combined Japan Integrated Staging score

	0 point	1 point	2 points	3 points
Score c-JIS
Child-Pugh stage	A	B	C
TNM stage by LCSGJ¹	I	II	III	IV
Score bm-JIS
Child-Pugh stage	A	B	C
TNM stage by LCSGJ¹	I	II	III	IV
Elevated tumor markers, n (AFP, AFP-L3, DCP)	0	1	2 or 3

¹Definitions of the TNM stage by the LCSGJ; Stage I: T1 (fulfilling 3 T factors) N0 M0; Stage II: T2 (fulfilling 2 T factors) N0 M0; Stage III: T3 (fulfilling 1 T factor) N0 M0; Stage IV: T4 (fulfilling 0 T factor) N0 M0 or any T N0 - 1 M1; T factor: (1) single; (2) < 2 cm; and (3) no vascular involvement. LCSGJ: Liver Cancer Study Group of Japan; bm-JIS: Biomarker combined-Japan Integrated Staging.

Citation: Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol 2016; 8(17): 703-715
URL: https://www.wjgnet.com/1948-5182/full/v8/i17/703.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i17.703